GlioblastomaGUAVANCT07052877
The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab
An observational study of Glioblastoma and Glioblastoma Multiforme (GBM), run by Royal North Shore Hospital at 1 site in Australia.
Trial summary
This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Glioblastoma, Glioblastoma Multiforme (GBM)
- What is being tested?
- PSMA PET/CT scan
- How many people
- 20 participants
- Where
- 1 siteAustralia
- Study dates
- 11 Dec 2025to Jul 2027
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Glioblastoma patients receiving Bevacizumab as part of standard of care.
Who may be able to join
- > 18 year of age
- ECOG 0-2
- Able to provide informed consent for the study
- Minimum of 1 month from completion of radiotherapy with clinical or radiography evidence suggesting residual tumour
- Confirmed glioblastoma IDH1/2 wildtype (WHO2021)
- For bevacizumab treatment as per treating physician
- Able to comply with trial requirements
Who cannot join
- No major organ impairment that would likely lead to unacceptable toxicities- eg significant cardiac, hepatic, renal or haematologic dysfunction (based on clinician assessment)
- Any contraindication to bevacizumab, MRI gadolinium contrast or 68Ga-PSMA-617 radioisotope
- Any implant, foreign body, 3T MRI incompatible device or other contraindication to MRI imaging
- Does not fulfill PBS requirements for bevacizumab
- Women lactating, pregnant or of child baring potential who are not willing to avoid pregnancy during the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Australia1 site, 1 recruiting
- Recruiting
Royal North Shore Hospital
Saint Leonards, New South Wales, 2065
Alexander Yuile, +61 2 94631171, Alexander.Yuile@health.nsw.gov.au
About this study
Official title: Investigating Glioblastoma PSMA Expression by Utilizing Anti-VEGF and Its Effect on PSMA PET Scan Avidity
This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.
- Conditions
- Glioblastoma, Glioblastoma Multiforme (GBM)
- Being tested
- PSMA PET/CT scan
- Keywords
- glioblastoma, anti-VEGF, PSMA, bevacizumab, VEGF, glioma, astrocytoma
- Medical subject headings
- Glioblastoma, Glioma, Astrocytoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PSMA PET/CT scanDiagnostic test
PSMA PET scan will be used to monitor changes in PSMA expression in response to bevacizumab.
| Study group | Role | What they receive |
|---|---|---|
| Patients with glioblastoma receiving Bevacizumab as part of their standard of care | Not described Receives: Diagnostic Test: PSMA PET/CT scan |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in PSMA PET metabolic tumour volume (MTV) before and after bevacizumab administration.
Measured: Prior to first administration of bevacizumab to 6 weeks after.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jul 2025
- Study start11 Dec 2025
- Primary completionJul 2027 (estimated)
- Study completionJul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GlioblastomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Royal North Shore Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Alexander Yuile, Royal North Shore Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07052877
- Sponsor's protocol ID
- GUAVA
- Acronym
- GUAVA
- Status last verified
- Aug 2026
- First submitted
- 23 Jun 2025
- Last updated
- 13 Aug 2026
- Results posted
- No
- FDA-regulated device
- No
- Individual data sharing
- No